FR2601245A1 - Nouvelle utilisation de la bromocriptine. - Google Patents

Nouvelle utilisation de la bromocriptine. Download PDF

Info

Publication number
FR2601245A1
FR2601245A1 FR8709849A FR8709849A FR2601245A1 FR 2601245 A1 FR2601245 A1 FR 2601245A1 FR 8709849 A FR8709849 A FR 8709849A FR 8709849 A FR8709849 A FR 8709849A FR 2601245 A1 FR2601245 A1 FR 2601245A1
Authority
FR
France
Prior art keywords
bromocriptine
disease
treatment
graves
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR8709849A
Other languages
English (en)
French (fr)
Inventor
Douglas Larson
Peter Hiestand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of FR2601245A1 publication Critical patent/FR2601245A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR8709849A 1986-07-14 1987-07-10 Nouvelle utilisation de la bromocriptine. Withdrawn FR2601245A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
FR2601245A1 true FR2601245A1 (fr) 1988-01-15

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8709849A Withdrawn FR2601245A1 (fr) 1986-07-14 1987-07-10 Nouvelle utilisation de la bromocriptine.

Country Status (13)

Country Link
JP (1) JPS6323817A (xx)
KR (1) KR880001292A (xx)
AU (1) AU602154B2 (xx)
CH (1) CH672987A5 (xx)
DE (1) DE3722383A1 (xx)
DK (1) DK363887A (xx)
FR (1) FR2601245A1 (xx)
GB (1) GB2192541B (xx)
IT (1) IT1224222B (xx)
NL (1) NL8701631A (xx)
PH (1) PH24525A (xx)
SE (1) SE8702843L (xx)
ZA (1) ZA875145B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5731287A (en) * 1988-05-10 1998-03-24 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
AU3419293A (en) * 1991-12-23 1993-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The A therapeutic process for the treatment of the pathologies of type II diabetes
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
EP2091537B1 (de) 2006-11-23 2013-05-22 Sinoxa Pharma GmbH Pharmazeutische zusammensetzungen zur behandlung von kapillarer arteriopathie
AU2017254650A1 (en) * 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
JP7231255B2 (ja) 2017-10-18 2023-03-01 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 改善されたブロモクリプチン製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE MERCK INDEX, édition 10, 1983, page 195, Merck & CO., Inc., Rahway, N.J., US; Monographie 1386: "Bromocriptine" *

Also Published As

Publication number Publication date
GB2192541A (en) 1988-01-20
DK363887A (da) 1988-01-15
NL8701631A (nl) 1988-02-01
DE3722383A1 (de) 1988-01-28
JPS6323817A (ja) 1988-02-01
GB2192541B (en) 1990-05-02
ZA875145B (en) 1989-02-22
AU602154B2 (en) 1990-10-04
IT8748160A0 (it) 1987-07-10
IT1224222B (it) 1990-09-26
AU7558787A (en) 1988-01-21
CH672987A5 (xx) 1990-01-31
DK363887D0 (da) 1987-07-13
GB8716323D0 (en) 1987-08-19
KR880001292A (ko) 1988-04-22
SE8702843L (sv) 1988-01-15
PH24525A (en) 1990-07-18
SE8702843D0 (sv) 1987-07-13

Similar Documents

Publication Publication Date Title
FR2601245A1 (fr) Nouvelle utilisation de la bromocriptine.
Beck et al. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly
EP2081564B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
Leung et al. Allergic and immunologic skin disorders
JP2001523663A (ja) 進歩した糖化最終生成物中間体及び後−アマドリ阻害
FR2522267A1 (fr) Glycoproteines a activite antitumorale, leur procede de preparation et leur application therapeutique
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
FR2541115A1 (fr) Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses
FR2530468A1 (fr) Composition analgesique et anti-inflammatoire contenant de l'ibuprofen
EP1083898B1 (fr) Nouvelle utilisation de composes inhibiteurs de la protease du vih
FR2797767A1 (fr) Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
Hatotani et al. Psychoendocrine model of depression
FR3004354A1 (fr) Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
EP1411961A1 (fr) Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
JP2002003391A (ja) エゾウコギを用いた薬剤並びに組成物及びその抽出方法
DE10297331T5 (de) Behandlung und Diagnose von Insulin-resistenten Zuständen
Stout et al. Effect of phenformin on lipid transport in hypertriglyceridemia
Alergant Treatment of gonorrhoea with amoxycillin.
EP0099775B1 (fr) Application du N-(diéthylaminoéthyl) 2-méthoxy-5-méthylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase
FR2569109A1 (fr) Nouvelles preparations pharmaceutiques
WO2008009798A1 (fr) Composition a base de d-glucosamine, de lactoferrine et de chondroitine sulfate pour prevenir et/ou pour traiter les maladies articulaires dégénératives
Heikinheimo Severe prolonged hypoglycemia following tolbutamide and carbutamide treatment
Krog-Meyer et al. Effect of amitriptyline on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression
FR2527630A1 (fr) Enzyme leucocytaire humaine de type pepsique, procede pour sa preparation et agent therapeutique la contenant
Lemaitre et al. SUN-598 Phenotypic Study of Meso-Somatous (Roch-Leri) Lipomatosis

Legal Events

Date Code Title Description
ST Notification of lapse